Axonyx: Posiphen may support stem cell transplantation in Alzheimer's disease

By Lisa Kerner

Erie, Pa., April 24 - Axonyx Inc. said results of an independent study show that Posiphen, the positive isomer of Phenserine, increased the ability of transplanted human neuronal stem cells to differentiate into neurons in APP transgenic mice, a model of Alzheimer's disease in humans.

The research showed that when APP transgenic mice had been pre-treated with Posiphen, transplanted human neuronal stem cells start to differentiate into neurons in the brain area where they are needed. When human neuronal stem cells were transplanted into the brains of APP transgenic mice in the absence of Posiphen, human neuronal stem cells did not differentiate into neurons.

Axonyx said the differentiation of stem cells into functioning neurons is critical to the success of stem cell therapy of Alzheimer's disease.

The research was presented at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer's Disease held last week in Geneva, Switzerland.

Axonyx, a New York-based biopharmaceutical company, develops pharmaceutical compounds for the treatment of central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.